Roche scores FDA nod for Evrysdi tablets, bolstering convenience edge over rivals
The FDA on Wednesday gave the thumbs up to a tablet formulation of Roche's Evrysdi to treat spinal muscular atrophy in adults and children ages 2 and older. The new tablets, which Roche plans to launch in the coming weeks, are expected to offer patients greater flexibility in how they manage their disease.
The FDA on Wednesday gave the thumbs up to a tablet formulation of Roche's Evrysdi to treat spinal muscular atrophy in adults and children ages 2 and older. The new tablets, which Roche plans to launch in the coming weeks, are expected to offer patients greater flexibility in how they manage their disease.
